Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0352W HIGH $1.19
Volume
569.00
Value Traded
0.35
Short % Float
0%
-99.38%5 Year
-99.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.14 M
EPS (TTM)
-15.19
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
0.00%
Institutions
0.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
PXMD Catalyst Timeline
Dated clinical, regulatory and corporate events for PaxMedica, Inc.
Past FDA Catalysts and PDUFA Decisions
How PXMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every PXMD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PAX-101 | African Sleeping Sickness | Phase 3 | 2023-07-24 | statistically significant and clinically meaningful resultsRead More | PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301 - The study's primary endpoint was reached and demonstrated statistically significRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rome ZacharyDirector | Sell | -811 15,148 held | $0.48 | 01/29/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in PXMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PXMD for Q2 2026. | ||||
Ownership Trends
PXMD Short Interest
Shares sold short, counted twice a month.
0%
Short % of Float
of tradable shares sold short
687
Shares Sold Short
0.0% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
936
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PXMD ranks across every disease it competes in
Competitive Position is a premium feature
See how PXMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPXMD News
PXMD▼ -53.5%on this news
PaxMedica Secures Immediate Exercise of Warrants
Secures Immediate Exercise of Warrants NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the im
Read more →PXMD▲ +27.3%on this news
PaxMedica Files Nasdaq Delisting Appeal Notice for Upcoming FDA Meeting on PAX-101
PaxMedica Files Nasdaq Delisting Appeal Notice for Upcoming FDA Meeting on PAX-101 TARRYTOWN, NY / ACCESSWIRE / May 15, 2024 / PaxMedica, Inc. (the "Company" or "PaxMedica")(OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, t
Read more →PXMDPaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 TARRYTOWN, NY / ACCESSWIRE / April 23, 2024 /, PaxMedica Inc. (Nasdaq: PXMD) (the "Company"), a leading biopharmaceutical company dedicated to advancing treatments for neu
Read more →PXMD▼ -10.8%on this news
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness Emergent shortages of the drug used to treat the most severe form of African sleeping sickness
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global d
Read more →PXMDPaxMedica Achieves Key Milestone in the Development And Provides Update on Potential NDA Submission
PaxMedica Achieves Key Milestone in the Development And Provides Update on Potential NDA Submission TARRYTOWN, NY / ACCESSWIRE / April 11, 2024 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announ
Read more →PXMD▼ -13%on this news
PXMD Investor Presentation February 2024 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3 2 Forward - Looking Statements This P
While the Company believes that its internal assumptions are reasonable, no independent source has verified such assumptions . This Presentation contains trademarks, trade names, or service marks belonging to other entities . The Company does not intend the use or display of othe
Read more →PXMD▼ -44%on this news· ran to -54% by day 1
PaxMedica Announces Pricing of $7.0 Million Public Offering TARRYTOWN, New York
PaxMedica Announces Pricing of $7.0 Million TARRYTOWN, New York, Nov. 20, 2023 (ACCESSWIRE) PaxMedica, Inc. (NASDAQ: PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its
Read more →PXMD▲ +11.5%on this news· ran to -55% by day 3shared move
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update TARRYTOWN, NY
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update TARRYTOWN, NY, Nov 15, 2023 (Accesswire) - PaxMedica, Inc. (Nasdaq: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensiv
Read more →PXMDPaxMedica Appoints David Hough M.D. as Chief Medical Officer Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY
PaxMedica Appoints David Hough M.D. as Chief Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, August 16, 2023 -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel
Read more →PXMDPaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update TARRYTOWN, NY
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update TARRYTOWN, NY, August 9, 2023- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies ("APT") for the tr
Read more →PXMD▲ +7.1%on this news
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301 - The study's primary endpoint was reached and demonstrated statistically signific
Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301 - The study's primary endpoint was reached and demonstrated statistically significant and clinically meaningful results - These results pave the way for filing
Read more →PXMDPaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years VoxNova will be responsible for physician registration, s
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC TARRYTOWN, NY and HUDSON, OH - July 6, 2023 - PaxMedica, Inc. (Nasdaq: PXMD) and Vox Nova LLC (VoxNova), a privately held corporation, today announced that they have signed an exclusive pharm
Read more →PXMD▲ +7.6%on this news
PaxMedica Enters Research Collaboration Agreement with PoloMar Health for Phase II Study in Autism Spectrum Disorder Collaboration Will Investigate a Next Generation Orally Delivered Anti-Purinergic Compound Proof-of-Con
PaxMedica Enters Research Collaboration Agreement PoloMar Health for Phase II Study in Autism Spectrum Disorder Collaboration Will Investigate a Next Generation Orally Delivered Anti-Purinergic Compound Proof-of-Concept Study Based on one of PaxMedica's Proprietary TARRYTOWN
Read more →PXMDPaxMedica Completes HAT-301 Registrational Trial for PAX-101 HAT-301 is the Pivotal Efficacy Study to Support Upcoming NDA Filing Top Line Results Planned for Release in July 2023 Tarrytown, N.Y.
HAT-301 Registrational Trial for PAX-101 HAT-301 is the Pivotal Efficacy Study to Support Upcoming NDA Filing Top Line Results Planned for Release in July 2023 June 1, 2023 - PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development
Read more →PXMDPaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023 Tarrytown, N.Y.
Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023 Tarrytown, N.Y. May 15, 2023 - PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therap
Read more →PXMD▲ +8%on this news
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results -Phase 3 Results for HAT-301 Retrospective Trial Expected in Second Half 2023- Fourth Quarter 2022 Highlights Initiated Phase 3 C
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results -Phase 3 Results for HAT-301 Retrospective Trial Expected in Second Half 2023- Fourth Quarter 2022 Highlights Tarrytown, N.Y. March 29, 2023 - PaxMedica, Inc. (Nasdaq: PXMD), a clinic
Read more →PXMD▲ +8.6%on this news
PaxMedica Releases 2022 Shareholder Letter Company Anticipates Multiple Milestones in Next 12-24 Months Tarrytown, NY
PaxMedica Releases 2022 Shareholder Letter Company Anticipates Multiple Milestones in Next Tarrytown, NY, February 15, 2023 -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies ("APT")
Read more →PXMD▼ -7.6%on this news· ran to -23% by day 1
PaxMedica , Inc. Proprietary Information. All rights reserved Addressing Urgent Needs In Serious Neurologic Disorders Nasdaq: PXMD December 2022 2 2022. PaxMedica , Inc. Proprietary Information. All rights reserved Cauti
Brucei Rhodesiense Human African Trypanosomiasis (HAT), aka African Sleeping Sickness, for over 100 years Currently only approved in Africa , where PaxMedica has the exclusive license to suramin - treated patient data from key endemic hospitals PAX - 101 received FDA Orphan Drug
Read more →PXMD▼ -9.6%on this news· ran to +24% by day 1
PaxMedica, Inc. Enters into Committed Equity Investment Agreement for up to $20 Million with Lincoln Park Capital -Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101- Tarrytown, N.Y.
Inc. Enters into Committed Equity Investment Agreement for up to $20 Million with Lincoln Park Capital Flexible Funding on Path to NDA Submission for PAX-101- Tarrytown, N.Y. November 17, 2022 - PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusin
Read more →PXMDPaxMedica Initiates Clinical Program to Advance PAX-101 towards FDA Submission Final Study Results are Expected in First Half of 2023 TARRYTOWN, NY
PaxMedica Initiates Clinical Program to Advance PAX-101 towards FDA Submission Final Study Results are Expected in First Half TARRYTOWN, NY, November 8, 2022 -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of anti-puri
Read more →About PaxMedica, Inc.
Headquarters303 South Broadway
Founded26-08-2022
BIOPHARMAWATCH ELITE
Trade the next PXMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime